Specialty Drug, Stop-Loss Laser, and a Mid-Year Denial Request
Alpine Health Systems, a self-funded employer with 1,400 employees, sponsors a medical plan with a $200,000 specific stop-loss deductible. For the current plan year, the stop-loss carrier applied an individual $350,000 laser to a participant with a rare autoimmune condition. The participant's physician has prescribed an FDA-approved biologic costing $420,000 per year. The plan document gives the administrator discretionary authority and excludes experimental or investigational treatment, but the drug is on-label and has no valid formulary exclusion. The plan's case-management vendor recommends approval with adherence monitoring. The CFO wants to deny coverage mid-year to avoid the $350,000 retained risk, arguing the laser makes the drug unaffordable. The participant has submitted a claim and requested an expedited appeal. The employer also has a $5 million aggregate stop-loss attachment and a $2,500 individual out-of-pocket maximum. The HR team asks whether it can amend the plan retroactively to exclude the drug or create a new exclusion for high-cost specialty drugs.
1. Can the plan administrator deny the claim under the plan as written? Explain the fiduciary and claims-process analysis.
Read the worked answer
The administrator should not deny the claim on the current record. A discretionary grant of authority under ERISA does not permit a denial that conflicts with the plan's written terms or the administrator's fiduciary duties. The plan excludes experimental or investigational treatment; this drug is FDA-approved and prescribed on-label, so that exclusion does not apply. There is no formulary exclusion for this drug. The stop-loss laser is a contract between the employer and its stop-loss carrier; it does not change the plan's obligation to pay covered benefits. A mid-year amendment to carve out this drug or all high-cost specialty drugs would be suspect: plan sponsors generally may amend prospectively, but a retroactive exclusion aimed at a single claimant's approved treatment raises fiduciary, communication, and possibly discrimination concerns. The participant has already requested an expedited appeal, so the plan must follow its ERISA claims procedure, provide a full and fair review, and meet the applicable deadline. The practical answer is to approve with case management, then consider a prospective, uniformly applied specialty-drug management program for the next plan year.
2. What are the stop-loss and budgeting implications if the plan pays the claim?
Read the worked answer
If the plan pays, the plan's net cost is not the full $420,000. The stop-loss laser sets the carrier's attachment point for this participant at $350,000; the employer retains the first $350,000 and the stop-loss carrier reimburses the excess, subject to the policy terms. The $200,000 specific deductible is subsumed or interacts with the laser as the policy provides, so the employer should confirm the exact retained amount with the stop-loss carrier in writing. Denying the claim would avoid the retained $350,000 only if the denial is upheld; it would also forfeit stop-loss reimbursement and create litigation, bad-faith, and participant-relations risk. The employer should model the aggregate attachment, the $2,500 out-of-pocket maximum, and any manufacturer copay assistance. For budgeting, assume the drug continues and consider a next-year stop-loss laser, a specialty pharmacy carve-out, and a formulary exception process with clinical criteria.
3. Recommend a compliant process for responding to the claim and future plan design.
Read the worked answer
The compliant process is to treat the claim as an urgent care claim, use the plan's expedited appeal procedures, and have a clinical reviewer who is independent of the CFO's cost concern evaluate the medical necessity and plan terms. The decision letter should state the specific plan provisions relied on, the clinical rationale, and appeal rights. The employer should not communicate with the participant in a way that singles her out or discloses protected health information. For future design, the plan can adopt a prospective specialty-drug management program with prior authorization, case management, and a clear exception process, but it must be in the plan document and SPD and applied consistently. The stop-loss policy should be reviewed before any plan change, because a mid-year exclusion may not reduce the employer's stop-loss exposure and may trigger a known-event dispute.